2-year data confirm benefit of nivolumab regimen for advanced gastric, esophageal cancers

2-year data confirm benefit of nivolumab regimen for advanced gastric, esophageal cancers

The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.However, results of the randomized phase 3 study showed the combination of nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) did not significantly improve survival compared with chemotherapy.“Nivolumab plus chemotherapy continues to demonstrate clinically meaningful benefit [as first-line treatment], and it is nice toRead More

Share on facebook
Share on twitter
Share on linkedin